Alector, LLC
953 Indiana Street
San Francisco
California
94107
United States
Tel: 415-231-5660
Website: http://alector.com/
About Alector, LLC
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
37 articles about Alector, LLC
-
With one disease-modifying therapy already reaching patients and another expected to soon, several biopharma companies anticipate key data for novel assets in the coming 12 months.
-
In a filing with the SEC, Abbvie's decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.
-
Suliman anticipates filing an Investigational New Drug application with the FDA for the PCD asset this year, and next year filing one for the cystic fibrosis asset.
-
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)
9/9/2021
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in a Phase 2 clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL001 in people with amyotrophic lateral sclerosis (ALS) who carry a C9orf72 mutation.
-
The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases.
-
CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia
6/2/2021
Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia.
-
Both sides claim to be pleased with arbitration results in dispute over Prevail CEO's alleged breach of contract from time with Allector.
-
Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China
3/25/2020
Innovent Biologics, Inc. and Alector, Inc. jointly announced that they have entered into a licensing agreement to develop and commercialize an anti-SIRP-alpha antibody for the treatment of oncology indications in China.
-
Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.
3/20/2020
Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. A
-
Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients
1/28/2020
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003.
-
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
-
Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day
12/13/2019
Reported results from analysis of the Phase 1b study of AL001 in patients with symptomatic FTD-GRN showing a statistically significant normalization in a number of disease-associated proteins and an initial trend of a decrease compared to baseline levels in plasma Neurofilament
-
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee
12/13/2019
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the appointment of Richard Scheller, Ph.D., and Thomas Südhof, M.D., as co-chairs of the Company’s Strategic Portfolio Advice and Review Committee (SPARC).
-
Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer
12/11/2019
Dr. Suliman will report to Arnon Rosenthal, Ph.D., chief executive officer of Alector.
-
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
12/6/2019
Alector, Inc., a clinical stage biotechnology company pioneering immuno-neurology, reported safety and biomarker data from the single ascending dose phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers.
-
Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia
9/9/2019
Alector, Inc., a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001.
-
Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors
8/12/2019
Alector, Inc. announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors.
-
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients
7/18/2019
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported initial positive data from a subset of patients in the company’s INFRONT clinical study of its product candidate, AL001. AL001 is being evaluated for the treatment of patients with frontotemporal dementia with a granulin mutation (FTD-GRN).
-
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
-
Winterlight is developing speech-based digital biomarkers to monitor disease progression in patients with FTD in collaboration with Alector
7/9/2019
Winterlight Labs Inc, a company that develops speech-based digital biomarkers for neuropsychiatric disorders, announced it is developing vocal biomarkers for monitoring disease progression in frontotemporal dementia patients in collaboration with Alector, a biotechnology company developing therapeutics for neurodegeneration.